
A02 The feedback loop among miR-449b-3p/ADAM17/NF-κB promotes metastasis in nasopharyngeal carcinoma. Qian Fei, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.

A03 Isolation, characterization and expansion of circulating tumor cells in head and neck cancers. Arutha Kulasinghe, The School of Biomedical Sciences, IHBI/QUT, Brisbane, QLD, Australia.

A04 Tumor development trajectories for exploring differences between cancer subtypes. Ignaty Leshchiner, Broad Institute of MIT and Harvard, Boston, MA, USA.

A05 CD44, total protein and p16 marker expression in oral rinses from oral and oropharyngeal cancer patients and controls. Drew Smith, FIU, Miami, FL, USA.

A06 Interrogation of HPV-positive oropharyngeal squamous cell carcinomas with RNA-based Nanostring assay demonstrates expression profile associated with treatment resistance. Paul Zolkind, Washington University School of Medicine, St. Louis, MO, USA.

A07 Improved prognosis of HPV-positive oropharyngeal cancers is associated with a suppression of TGF-β-mediated immune evasion. Pinaki Bose, University of Calgary, Calgary, AB, Canada.

A08 Resolving STING-mediated tumor immune microenvironment shift at single-cell resolution. Blake Heath, University of Michigan, Ann Arbor, MI, USA.

A09 Activation of the CD45 receptor on leukocytes by the C24D peptide results in immune mediated head and neck squamous cell carcinoma apoptosis. Aviram Mizrachi, Rabin Medical Center, Petah Tikva, Israel.

A10 Treatment of squamous cell carcinoma by alpha radiation-based brachytherapy (Alpha DaRT). Aviram Mizrachi, Rabin Medical Center, Petah Tikva, Israel.

A11 STAT1 mediates resistance to experimental oral cancer which is associated with enhanced anti-tumor T cell responses. Steve Oghumu, Ohio State University, Columbus, OH, USA.

A12 Metformin treatment in LAHNSCC induces an anti-tumorigenic immune response. Sarah Palackdharry, University of Cincinnati, Cincinnati, OH, USA.
A13 Neoadjuvant PD-1 mAb treatment induces post-operative immune memory responses against both immunodominant and immunorecessive antigens. Clint Allen, National Institutes of Health, Bethesda, MD, USA.

A14 The p53R172H gain-of-function mutation promotes resistance to oral cancer immunoprevention. Carlos Caulin, University of Arizona, Tucson, AZ, USA.

A15 Integrated biomarker trials to evaluate myeloid and lymphoid composition of HNSCC and solid tumors treated with pepinemab and combinations with checkpoint inhibitors. Elizabeth Evans, Vaccinex, Rochester, NY, USA.

A16 Natural killer cell therapy efficacy is enhanced through inhibition of myeloid derived suppressor cell trafficking. Clint Allen, National Institutes of Health, Bethesda, MD, USA.

A17 Neutrophil-to-lymphocyte ratio predicts response to neoadjuvant presurgical PD-1 inhibition in oral cancer. Joshua Horton, Medical University of South Carolina, Charleston, SC, USA.

A18 Personalized RNA nanoparticles remodel the HNSCC immunologic milieu to unlock immunotherapeutic activity. Natalie Silver, University of Florida, Gainesville, FL, USA.

A19 Opioid prescriptions in the military defense system head and neck cancer population, FY2007 - FY2014. Art Ambrosio, Naval Medical Center San Diego, San Diego, CA, USA.

A20 Dysgeusia may play a role in negatively affecting mood and anxiety in post-radiation head and neck patients. Thomas Arnell, Larner College of Medicine at UVM, Burlington, VT, USA.

A21 Increasing use of adjuvant radiation for parathyroid carcinoma is associated with improved survival outcomes: A population-based study. Richard Cannon, University of Utah, Salt Lake City, UT, USA.

A22 Patient-derived organoids recapitulate response heterogeneity in head and neck cancer. Vincent Vui King Chong, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

A23 Transoral robotic surgery for primary oncologic resection: Outcomes from a rural academic medical center. Eric Eisen, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.
A24 Multitiered assessment of the incidence and demographics of patients with multiple human papillomavirus-mediated head and neck cancers. Daniel Faden, MEEI, Boston, MA, USA.

A25 Chromatin structure regulates cancer-specific alternative splicing events in primary HPV-related oropharyngeal squamous cell carcinoma. Daria Gaykalova, Johns Hopkins University, Baltimore, MD, USA.

A26 Genomic and epigenomic analysis reveal a distinct and targetable transcriptional signature of HNSCC subtypes. Christian Gluck, Jacobs School of Medicine and Biomedical Science, University at Buffalo, Buffalo, NY, USA.

A27 Differential protein-interactome of MYB-NF1B fusion in adenoid cystic carcinoma. Patrick K. Ha, UCSF, San Francisco, CA, USA.

A28 Predictive factors for mortality after surgery alone for human papilloma virus associated oropharynx squamous cell carcinoma: Analysis of the National Cancer Database. Mary Han, School of Medicine, University of California-San Francisco, San Francisco, CA, USA.

A29 Association of support group attendance with quality of life metrics in head and neck cancer patients. Kyohei Itamura, Keck School of Medicine of USC, Los Angeles, CA, USA.

A30 Association of pretreatment BMI with risk of head and neck cancer: A large-scale single-center study. Anshu Khanna, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

A31 Deregulation of NOTCH 1/NR4A2 signaling axis in head and neck cancer pathogenesis. Muzafar Macha, University of Nebraska Medical Center, Omaha, NE, USA.

A32 Postoperative analgesia in a Ugandan population. Jason Thuener, Case Western Reserve University School of Medicine, Cleveland, OH, USA.

A33 Fungal beta-glucans, EphA2 and oral cancer: Preliminary observations. Jason Thuener, Case Western Reserve University School of Medicine, Cleveland, OH, USA.

A34 Effect of microvesicles on metalloproteinases secretion by myoepithelial cells. Gabriel Rena, São Leopoldo Mandic Faculty of Medicine, Campinas, SP, Brazil.
A35 Diagnostic performance and timing of post-treatment 18F-FDG PET/CT for head and neck cancer surveillance: a meta-analysis of reported studies. Adam Dmytriw, University of Toronto, Toronto, ON, Canada.

A36 Impact of feeding tube use on swallowing-related quality of life and weight in oropharyngeal cancer. Nedeljko Jovanovic, Western University, London, ON, Canada.


A41 Molecular factors impacting oropharyngeal cancer prognosis. Alina Diaconesco, McGill, Montreal, QC, Canada.

A42 Total laryngopharyngoesophagectomy with gastric transposition for hypopharyngeal cancer: A tertiary care center experience. Prerit Rao, Kasturba Medical College, Manipal, Karnataka, India.